Articles

*Information from these resources may not always be relevant for everyone. Please check with your doctor before making any changes to your health and/or lifestyle.

October 2025

FDA Approves Gazyva®- Lupus Foundation of America

  • The Gazyva® (obinutuzumab) has been approved by the U.S. Food & Drug Administration (FDA) for the treatment of adults with lupus nephritis — a serious kidney-involving complication of systemic lupus erythematosus (SLE).

  • In a Phase III study (the REGENCY trial), 46.4% of patients receiving Gazyva plus standard therapy achieved a complete renal response by week 76, compared to 33.1% of patients receiving standard therapy alone, demonstrating a statistically significant improvement. Genentech+2Lupus Therapeutics+2

  • Gazyva is the only anti-CD20 monoclonal antibody to show this level of benefit in lupus nephritis in a randomized Phase III trial — marking an important new option for a condition where many patients still progress to kidney failure despite existing treatments.

November 2024

Charter to improve care for SLE - World Lupus Federation

  • A charter to improve care for systemic lupus erythematosus M. Mosca, J. Andersen, P. Wildman, S. Manzi, Z. Amoura, I. Bultink, O.A. Monticielo, S. Navarra, S. Pettersson

  • Read full study here

  • Review infographic here

April 2024

A Thousand Faces of Inequity - Lupus Canada

  • Article from By Stephanie Keeling, MD, MSc, FRCPC; Antonio Avina-Zubieta, MD, MSc, PhD, FRCPC; Sasha Bernatsky, MD, PhD; Ann Clarke, MD; Heather Coates; Paul Fortin, MD, MPH, FRCPC; Lourdes Gonzalez Arreola; Cheryl Koehn; Alexandra Legge, MD, FRCPC; Kelly Lendvoy; Leanne Mielczarek; Christine Peschken, MD, MSc, FRCPC; Zahi Touma, MD, PhD, FACP, FACR; Evelyne Vinet, MD, PhD

July 2021

Hydroxychloroquine is associated with lower risk of developing endometriosis in women with lupus - Lupus Foundation of America

  • Full study conducted by Fung-Yu Chen, Shou-Wei Chen, Xinpeng Chen, Jing-Yan Huang, Zhizhong Ye, James Cheng-Chung Wei

  • Read full study here

Gradual Glucocorticosteroid Withdrawal Is Safe in Clinically Quiescent Systemic Lupus Erythematosus - American College of Rheumatology

  • Download PDF version here

Study Finds Reducing Pain, Fatigue, and Flares are Top Treatment Goals for People with Lupus - Lupus Foundation of America

  • Full study conducted by Julie A. Birt, Monica A. Hadi, Nashmel Sargalo, Ella Brookes, Paul Swinburn, Leslie Hanrahan, Karin Tse, Natalia Bello, Kirstin Griffing, Maria E. Silk, Laure A. Delbecque, Diane Kamen & Anca D. Askanase for Rheumatology and Therapy

  • Read full study here